BRINZOLAMIDE BRIMONIDINE MARKET

INTRODUCTION

Brinzolamide/brimonidine, marketed as Simbrinza, is a fixed-dose combination drug used to reduce intraocular pressure (pressure inside the eye) in individuals with ocular hypertension (high intraocular pressure) or open-angle glaucoma. Brimonidine tartrate and brinzolamide are also present. It's a type of eye drop.\

Ocular hyperaemia (red eye), allergic reactions in the eye, and dysgeusia are the most common side effects (taste disturbances).

Open-angle glaucoma (a condition in which the aqueous humour, the watery fluid inside the eyeball, cannot drain correctly) and other causes of excessive eye pressure raise the risk of retinal and optic nerve damage (the nerve that sends signals from the eye to the brain).

This can lead to severe vision loss and perhaps blindness. Brimonidine tartrate and brinzolamide, the active ingredients, help to lower intraocular pressure by decreasing the formation of aqueous humour.

Brinzolamide inhibits an enzyme called carbonic anhydrase, which creates bicarbonate, which is required for the creation of aqueous humour, whereas brimonidine tartrate inhibits another enzyme called adenylate cyclase, which is also involved in the generation of aqueous humour. Brimonidine also enhances aqueous humour drainage from the front of the eye.

BRINZOLAMIDE BRIMONIDINE MARKET SIZE AND FORECAST

The Global BRINZOLAMIDE brimonidine market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

BRINZOLAMIDE BRIMONIDINE MARKET RECENT DEVELOPMENT

Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension. The main risk factor for the onset and progression of open-angle glaucoma, or for the transformation of ocular hypertension into glaucoma, which may worsen the visual field if untreated, is elevated intraocular pressure (IOP). The cornerstone of treatment for ocular hypertension and open-angle glaucoma is IOP reduction.

Guidelines from the European Glaucoma Society recommend starting treatment with a monotherapy of prostaglandin analogues (PGAs), which are efficient first-line ocular hypertensives.

However, long-term goal IOP achieving and maintenance may not be possible with monotherapy: After 2–5 years of treatment, 40%–75% of individuals need two or more drugs to reduce their IOP enough. 

During the first several years of treatment, 50% of patients need to switch from their original monotherapy, with insufficient IOP-lowering accounting for 80% of these cases.

Multiple medication use or frequent dosing can reduce patient adherence to therapy and persistence, which may result in an insufficient reduction of IOP. Fixed-dose combos reduce the frequency of administration and exposure to preservatives while offering the convenience of two or more drugs in a single formulation.

Therefore, using fixed-dose combinations may enhance patient comfort, treatment adherence, and persistence. Although topical -blockers are typically included in fixed-dose combination regimens for the treatment of glaucoma, many glaucoma patients have contraindications to this medication.

The only fixed-dose combination of ophthalmic suspension without a -blocker is brinzolamide 10 mg/mL/brimonidine 2 mg/mL. Patients with open-angle glaucoma or ocular hypertension should take BBFC three times daily in the United States and twice daily in the European Union.

Patients with open-angle glaucoma or ocular hypertension who were not sufficiently treated by PGA monotherapy have shown that BBFC dosed three times daily can significantly lower IOP.

However, there is no data on a twice-daily BBFC regimen taken in addition to PGA. In this experiment, individuals with open-angle glaucoma or ocular hypertension who were not adequately controlled on a PGA were assessed for the additive IOP-lowering effects of twice-daily BBFC.

BRINZOLAMIDE BRIMONIDINE MARKET COMPANY PROFILES

• Aerie Pharmaceuticals Inc
• ALLERGAN
• Novartis AG
• Abbott Healthcare
• Johnson & Johnson

THIS BRINZOLAMIDE BRIMONIDINE MARKET REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many BRINZOLAMIDE brimonidine  are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global BRINZOLAMIDE brimonidine  and key vendor selection criteria
3. Where is the BRINZOLAMIDE brimonidine  manufactured? What is the average margin per unit?
4. Market share of Global BRINZOLAMIDE brimonidine  market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global BRINZOLAMIDE brimonidine  in-house
6. key predictions for next 5 years in Global BRINZOLAMIDE brimonidine  market
7. Average B-2-B BRINZOLAMIDE brimonidine  market price in all segments
8. Latest trends in BRINZOLAMIDE brimonidine  market, by every market segment
9. The market size (both volume and value) of the BRINZOLAMIDE brimonidine  market in 2024-2030 and every year in between?
10. Production breakup of BRINZOLAMIDE brimonidine  market, by suppliers and their OEM relationship